ClinicalTrials.gg
CompletedNCT04811040Updated Jan 27, 2025Results posted

Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection

A Phase 1 interventional study of Oral Lenacapavir and Subcutaneous Lenacapavir in HIV-1 Infection, sponsored by Gilead Sciences. Completed at 23 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the safety and tolerability of a combination of the broadly neutralizing antibodies (bNAbs) teropavimab (formerly GS-5423) and zinlirvimab (formerly GS-2872) in combination with the HIV capsid inhibitor lenacapavir (LEN).

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • On antiretroviral therapy (ART) for ≥ 2 years prior to screening. A change in ART regimen ≥ 28 days prior to screening for reasons other than virologic failure (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed
  • No documented historical resistance to the current ART regimen
  • Plasma -1 RNA \< 50 copies/mL at screening
  • Documented plasma HIV-1 RNA \< 50 copies/mL for ≥ 18 months preceding the screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL). Unconfirmed virologic elevations of ≥ 50 copies/mL (transient detectable viremia, or "blip") prior to screening are acceptable.
  • Proviral phenotypic sensitivity to both teropavimab and zinlirvimab at screening by the PhenoSense mAb Assay (Monogram Biosciences) for inclusion in the Primary Cohort; sensitivity at screening by the PhenoSense mAb Assay (Monogram Biosciences) to 1 mAb, either teropavimab or zinlirvimab, within 18 months prior to enrollment for inclusion in the optional Pilot Cohort

    -- In both cohorts, teropavimab sensitivity is defined as 90% inhibitory concentration (IC90) ≤ 2 μg/mL; zinlirvimab sensitivity is defined as IC90 ≤ 2 μg/mL;

  • Cluster determinant 4+ (CD4+) count nadir ≥ 350 cells/μL
  • Screening ≥ 500 cells/μL
  • Availability of a fully active alternative ART regimen, in the opinion of the investigator, in the event of discontinuation of the current ART regimen with development of resistance

Key Exclusion Criteria:

  • Comorbid condition requiring ongoing
  • Evidence of current virus (HBV) infection
  • Evidence of current virus (HCV) infection (prior infection cleared spontaneously or with treatment is acceptable)
  • History of opportunistic infection or illness indicative of Stage 3 HIV disease

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Primary Cohort: Lenacapavir (LEN) + Teropavimab + Zinlirvimab 10 mg/kg

    Participants will receive a loading dose of 600 milligrams (mg) LEN orally on Day 1 and Day 2, along with 927 mg LEN as subcutaneous (SC) injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 10 mg/kg zinlirvimab as an intravenous (IV) infusion on Day 1.

    Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab

  • Experimental
    Primary Cohort: LEN + Teropavimab + Zinlirvimab 30 mg/kg

    Participants will receive a loading dose of 600 mg LEN orally on Day 1 and Day 2, along with 927 mg LEN as SC injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 30 mg/kg zinlirvimab as an IV infusion on Day 1.

    Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab

  • Experimental
    Pilot Cohort: LEN +Teropavimab +Zinlirvimab 10 mg/kg

    Participants will receive a loading dose of 600 mg LEN orally on Day 1 and Day 2, along with 927 mg LEN as SC injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 10 mg/kg zinlirvimab as an IV infusion on Day 1.

    Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab

  • Experimental
    Pilot Cohort: LEN +Teropavimab +Zinlirvimab 30 mg/kg

    Participants will receive a loading dose of 600 mg LEN orally on Day 1 and Day 2, along with 927 mg LEN as SC injection on Day 1. Thereafter, participants will receive 30 mg/kg teropavimab and then 30 mg/kg zinlirvimab as an IV infusion on Day 1.

    Drug: Oral Lenacapavir · Drug: Subcutaneous Lenacapavir · Drug: Teropavimab · Drug: Zinlirvimab

Interventions

  • Tablets administered without regard to food

    Also known as: GS-6207

  • Administered in the abdomen via subcutaneous injections

    Also known as: GS-6207

  • Administered intravenously

    Also known as: 3BNC117-LS, GS-5423

  • Administered intravenously

    Also known as: 10-1074-LS, GS-2872

06

What researchers measure

Primary outcomes

  1. Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)

    A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs. These events had an onset date on or after the study drug start date and prior to the last exposure date of long-acting (LA) regimen period for the LA regimen period analysis. The long acting regimen period included participants who were randomized and received at least one dose of the complete LA study drug regimen (ie, SC LEN + Teropavimab + Zinlirvimab).

    Time frame: Day 1 up to Week 26

Secondary outcomes

  1. Primary Cohort: Percentage of Participants With Human Immunodeficiency Virus- 1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 26 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. Week 26 window was between Days 176 and 224 (inclusive).

    Time frame: Week 26

  2. Primary Cohort: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm

    The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants a) who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to AE or death and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Week 26 window was between Days 176 and 224 (inclusive).

    Time frame: Week 26

  3. Primary Cohort: Percentage of Participants With Positive Anti-Teropavimab Antibodies

    Anti-teropavimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.

    Time frame: Week 26

  4. Primary Cohort: Percentage of Participants With Positive Anti-zinlirvimab Antibodies

    Anti-zinlirvimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.

    Time frame: Week 26

  5. Primary Cohort: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 26

    Time frame: Baseline; Week 26

  6. Primary Cohort: Number of Participants Who Develop Treatment-Emergent Resistance to LEN, Teropavimab, and Zinlirvimab

    Participants in the Resistance Analysis Population analyzed for this outcome included any participant who had received 1 dose of study drug, maintained their study drug regimen, and met one of the following virologic failure criteria: * Participants with HIV-1 RNA \>/= 200 copies/mL on 2 consecutive visits * Participants with HIV-1 RNA \>/= 200 copies/mL at study discontinuation or Week 26.

    Time frame: Day 1 up to Week 26

  7. Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    TEAEs were those adverse events that began on or after the first dose date of study drug and prior to last exposure date of LA regimen from participants who prematurely discontinued study or completed study, or any adverse events led to premature study drug discontinuation.

    Time frame: Day 1 up to Week 26

  8. Primary Cohort: Pharmacokinetic (PK) Parameter: AUC0-26 of Teropavimab

    AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.

    Time frame: Predose and at End of Infusion (EOI) of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26

  9. Primary Cohort: PK Parameter: AUC0-26 of Zinlirvimab

    AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26

  10. Primary Cohort: PK Parameter: AUClast of Teropavimab

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  11. Primary Cohort: PK Parameter: AUClast of Zinlirvimab

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  12. Primary Cohort: PK Parameter: T1/2 of LEN

    T1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  13. Primary Cohort: PK Parameter: T1/2 of Teropavimab

    T1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  14. Primary Cohort: PK Parameter: T1/2 of Zinlirvimab

    T1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  15. Primary Cohort: PK Parameter: Cmax of Teropavimab

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  16. Primary Cohort: PK Parameter: Cmax of Zinlirvimab

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  17. Primary Cohort: PK Parameter: Tmax of Teropavimab

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  18. Primary Cohort: PK Parameter: Tmax of Zinlirvimab

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  19. Primary Cohort: PK Parameter: Tlast of LEN

    Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  20. Primary Cohort: PK Parameter: Tlast of Teropavimab

    Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  21. Primary Cohort: PK Parameter: Tlast of Zinlirvimab

    Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).

    Time frame: Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)

  22. Primary Cohort: PK Parameter: C26week of LEN

    C26week is the concentration at week 26.

    Time frame: Week 26

  23. Primary Cohort: PK Parameter: C26week of Teropavimab

    C26week is the concentration at week 26.

    Time frame: Week 26

  24. Primary Cohort: PK Parameter: C26week of Zinlirvimab

    C26week is the concentration at week 26.

    Time frame: Week 26

07

Results

Posted Jan 27, 2025

Participant flow

Participants were enrolled at study sites in the United States.

Participant flow — Overall Study
MilestonePrimary Cohort: Lenacapavir (LEN)+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Started111056
Completed8956
Not completed3100
Withdrew: Lost to follow-up2000
Withdrew: Withdrew consent1100

Outcome measures

PrimaryPrimary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)

A treatment emergent SAE was defined as an event that, at any dose, resulted in the following: death; life-threatening situation; in-patient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; a congenital anomaly/birth defect; a medically important event or reaction: such events may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent one of the other outcomes constituting SAEs. These events had an onset date on or after the study drug start date and prior to the last exposure date of long-acting (LA) regimen period for the LA regimen period analysis. The long acting regimen period included participants who were randomized and received at least one dose of the complete LA study drug regimen (ie, SC LEN + Teropavimab + Zinlirvimab).

Time frame:
Day 1 up to Week 26
Reported as:
Number · percentage of participants
Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)
percentage of participantsPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs)00
SecondaryPrimary Cohort: Percentage of Participants With Human Immunodeficiency Virus- 1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 26 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA \< 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants who had the last available on-treatment HIV-1 RNA \< 50 copies/mL in the Week 26 analysis window. Week 26 window was between Days 176 and 224 (inclusive).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Primary Cohort: Percentage of Participants With Human Immunodeficiency Virus- 1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 26 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm
percentage of participantsPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: Percentage of Participants With Human Immunodeficiency Virus- 1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/mL at Week 26 as Determined by the US Food and Drug Administration (FDA)-Defined Snapshot Algorithm90.0 (55.5 to 99.7)90.0 (55.5 to 99.7)
SecondaryPrimary Cohort: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm

The percentage of participants with HIV-1 RNA ≥ 50 copies/mL at Week 26 was analyzed using the snapshot algorithm, which defined a participant's virologic outcome and included participants a) who had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL in the Week 26 analysis window; b) who did not have on-treatment HIV-1 RNA data in the Week 26 analysis window and i) discontinued study drug prior to or in the Week 26 analysis window due to lack of efficacy, or ii) discontinued study drug prior to or in the Week 26 analysis window due to AE or death and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL, or iii) discontinued study drug prior to or in the Week 26 analysis window due to reasons other than AE, death, or lack of efficacy and had the last available on-treatment HIV-1 RNA ≥ 50 copies/mL. Week 26 window was between Days 176 and 224 (inclusive).

Time frame:
Week 26
Reported as:
Number · percentage of participants
Primary Cohort: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm
percentage of participantsPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 26 as Determined by the US FDA-defined Snapshot Algorithm10.0 (0.3 to 44.5)0 (0.0 to 30.8)
SecondaryPrimary Cohort: Percentage of Participants With Positive Anti-Teropavimab Antibodies

Anti-teropavimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Primary Cohort: Percentage of Participants With Positive Anti-Teropavimab Antibodies
percentage of participantsPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: Percentage of Participants With Positive Anti-Teropavimab Antibodies50.010.0
SecondaryPrimary Cohort: Percentage of Participants With Positive Anti-zinlirvimab Antibodies

Anti-zinlirvimab antibodies positive participants are participants with positive treatment-emergent anti-drug antibody.

Time frame:
Week 26
Reported as:
Number · percentage of participants
Primary Cohort: Percentage of Participants With Positive Anti-zinlirvimab Antibodies
percentage of participantsPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: Percentage of Participants With Positive Anti-zinlirvimab Antibodies40.020.0
SecondaryPrimary Cohort: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 26
Time frame:
Baseline; Week 26
Reported as:
Mean · cells per microliter (cells/µL)
Primary Cohort: Change From Baseline in Cluster Determinant 4+ (CD4+) Cell Count at Week 26
cells per microliter (cells/µL)Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Baseline903 ± 303.71086 ± 333.6
Week 26-25 ± 241.6-5 ± 162.2
SecondaryPrimary Cohort: Number of Participants Who Develop Treatment-Emergent Resistance to LEN, Teropavimab, and Zinlirvimab

Participants in the Resistance Analysis Population analyzed for this outcome included any participant who had received 1 dose of study drug, maintained their study drug regimen, and met one of the following virologic failure criteria: * Participants with HIV-1 RNA \>/= 200 copies/mL on 2 consecutive visits * Participants with HIV-1 RNA \>/= 200 copies/mL at study discontinuation or Week 26.

Time frame:
Day 1 up to Week 26
Reported as:
Count of participants · Participants
Primary Cohort: Number of Participants Who Develop Treatment-Emergent Resistance to LEN, Teropavimab, and Zinlirvimab
ParticipantsPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Participants who developed resistance to LEN1—
Participants who developed resistance to Teropavimab0—
Participants who developed resistance to Zinlirvimab0—
SecondaryPrimary Cohort: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

TEAEs were those adverse events that began on or after the first dose date of study drug and prior to last exposure date of LA regimen from participants who prematurely discontinued study or completed study, or any adverse events led to premature study drug discontinuation.

Time frame:
Day 1 up to Week 26
Reported as:
Number · percentage of participants
Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)90100
SecondaryPrimary Cohort: Pharmacokinetic (PK) Parameter: AUC0-26 of Teropavimab

AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.

Time frame:
Predose and at End of Infusion (EOI) of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26
Reported as:
Mean · day* μg/mL
Primary Cohort: Pharmacokinetic (PK) Parameter: AUC0-26 of Teropavimab
day* μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: Pharmacokinetic (PK) Parameter: AUC0-26 of Teropavimab30500 ± 227031600 ± 3750
SecondaryPrimary Cohort: PK Parameter: AUC0-26 of Zinlirvimab

AUC0-26 is defined as the concentration of drug over time from Week zero to Week 26.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26
Reported as:
Mean · day* μg/mL
Primary Cohort: PK Parameter: AUC0-26 of Zinlirvimab
day* μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: AUC0-26 of Zinlirvimab14800 ± 209046100 ± 4180
SecondaryPrimary Cohort: PK Parameter: AUClast of Teropavimab

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Mean · day* μg/mL
Primary Cohort: PK Parameter: AUClast of Teropavimab
day* μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: AUClast of Teropavimab32900 ± 314034400 ± 5500
SecondaryPrimary Cohort: PK Parameter: AUClast of Zinlirvimab

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Mean · day* μg/mL
Primary Cohort: PK Parameter: AUClast of Zinlirvimab
day* μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: AUClast of Zinlirvimab17100 ± 264054700 ± 5290
SecondaryPrimary Cohort: PK Parameter: T1/2 of LEN

T1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · day
Primary Cohort: PK Parameter: T1/2 of LEN
dayPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: T1/2 of LEN65.8 (33.9 to 99.3)69.8 (55.1 to 140)
SecondaryPrimary Cohort: PK Parameter: T1/2 of Teropavimab

T1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · day
Primary Cohort: PK Parameter: T1/2 of Teropavimab
dayPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: T1/2 of Teropavimab65.2 (54.3 to 78.3)70.5 (57.5 to 89.6)
SecondaryPrimary Cohort: PK Parameter: T1/2 of Zinlirvimab

T1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · day
Primary Cohort: PK Parameter: T1/2 of Zinlirvimab
dayPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: T1/2 of Zinlirvimab76.7 (43.4 to 113)84.5 (71.6 to 149)
SecondaryPrimary Cohort: PK Parameter: Cmax of Teropavimab

Cmax is defined as the maximum observed concentration of drug.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Mean · μg/mL
Primary Cohort: PK Parameter: Cmax of Teropavimab
μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: Cmax of Teropavimab1090 ± 1601090 ± 222
SecondaryPrimary Cohort: PK Parameter: Cmax of Zinlirvimab

Cmax is defined as the maximum observed concentration of drug.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Mean · μg/mL
Primary Cohort: PK Parameter: Cmax of Zinlirvimab
μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: Cmax of Zinlirvimab378 ± 57.51110 ± 187
SecondaryPrimary Cohort: PK Parameter: Tmax of Teropavimab

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · hours
Primary Cohort: PK Parameter: Tmax of Teropavimab
hoursPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: Tmax of Teropavimab1.16 (1.02 to 2.75)2.24 (0.983 to 2.83)
SecondaryPrimary Cohort: PK Parameter: Tmax of Zinlirvimab

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · hours
Primary Cohort: PK Parameter: Tmax of Zinlirvimab
hoursPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: Tmax of Zinlirvimab1.10 (0.983 to 1.37)1.00 (0.850 to 1.23)
SecondaryPrimary Cohort: PK Parameter: Tlast of LEN

Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · day
Primary Cohort: PK Parameter: Tlast of LEN
dayPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: Tlast of LEN364 (168 to 366)364 (84.0 to 373)
SecondaryPrimary Cohort: PK Parameter: Tlast of Teropavimab

Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · day
Primary Cohort: PK Parameter: Tlast of Teropavimab
dayPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: Tlast of Teropavimab364 (168 to 366)364 (83.9 to 373)
SecondaryPrimary Cohort: PK Parameter: Tlast of Zinlirvimab

Tlast is defined as the time (observed time point) of Clast (the last observable concentration of drug).

Time frame:
Predose and at EOI of teropavimab and zinlirvimab on Day 1; Weeks 4, 8, 12, 16, 20, 24, 26, 38, 52, up to end of study (up to Week 55)
Reported as:
Median · day
Primary Cohort: PK Parameter: Tlast of Zinlirvimab
dayPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: Tlast of Zinlirvimab364 (168 to 366)364 (83.9 to 373)
SecondaryPrimary Cohort: PK Parameter: C26week of LEN

C26week is the concentration at week 26.

Time frame:
Week 26
Reported as:
Mean · ng/mL
Primary Cohort: PK Parameter: C26week of LEN
ng/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: C26week of LEN27.2 ± 17.422.5 ± 17.0
SecondaryPrimary Cohort: PK Parameter: C26week of Teropavimab

C26week is the concentration at week 26.

Time frame:
Week 26
Reported as:
Mean · μg/mL
Primary Cohort: PK Parameter: C26week of Teropavimab
μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: C26week of Teropavimab38.4 ± 5.8942.7 ± 6.49
SecondaryPrimary Cohort: PK Parameter: C26week of Zinlirvimab

C26week is the concentration at week 26.

Time frame:
Week 26
Reported as:
Mean · μg/mL
Primary Cohort: PK Parameter: C26week of Zinlirvimab
μg/mLPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Primary Cohort: PK Parameter: C26week of Zinlirvimab27.2 ± 6.4484.6 ± 27.1

Adverse events

Collected over All-Cause Mortality: Up to 55.9 weeks; Adverse Events: Up to 51.1 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg0/11 (0%)2/11 (18.2%)9/11 (81.8%)
Primary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg0/10 (0%)0/10 (0%)10/10 (100%)
Pilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kg0/5 (0%)1/5 (20%)4/5 (80%)
Pilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent serious events
Most frequent serious events
EventPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Soft tissue infectionInfections and infestations0/110/101/50/6
Myocardial infarctionCardiac disorders1/110/100/50/6
PneumoniaInfections and infestations1/110/100/50/6
Most frequent other events
Showing 10 of 92
Most frequent other events
EventPrimary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kg
Injection site indurationGeneral disorders2/114/100/53/6
Injection site painGeneral disorders5/115/100/52/6
Injection site erythemaGeneral disorders4/113/100/52/6
Injection site noduleGeneral disorders4/112/101/51/6
Covid-19Infections and infestations4/111/101/51/6
Injection site pruritusGeneral disorders1/110/100/52/6
Injection site massGeneral disorders3/111/100/50/6
Upper respiratory tract infectionInfections and infestations3/110/100/51/6
LymphadenopathyBlood and lymphatic system disorders0/112/100/50/6
Conjunctival haemorrhageEye disorders0/110/101/50/6

Baseline characteristics

The Safety Analysis Set included all randomized participants who have received at least one dose of study drug.

Age, Categorical
Age, Categorical(Participants)Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgTotal
<=18 years00000
Between 18 and 65 years11105632
>=65 years00000
Age, Continuous
Age, Continuous(years)Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgTotal
Mean45 ± 9.841 ± 11.147 ± 15.146 ± 11.444 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgTotal
Female03216
Male1173526
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgTotal
Hispanic or Latino432110
Not Hispanic or Latino773522
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgTotal
Race — White753318
Race — Black or African American12227
Race — Other or More Than One Race12014
Race — Asian21003
Region of Enrollment
Region of Enrollment(Participants)Primary Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPrimary Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 10 mg/kgPilot Cohort: LEN+Teropavimab+Zinlirvimab 30 mg/kgTotal
United States11105632
08

Study locations

23 sites
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Mills Clinical Research
    Los Angeles, California 90069, United States
  • One Community Health
    Sacramento, California 95811, United States
  • UCSD AntViral Research Center (AVRC)
    San Diego, California 92103, United States
  • Yale University; School of Medicine; AIDS Program
    New Haven, Connecticut 06510, United States
  • Midway Immunology and Research Center
    Fort Pierce, Florida 34982, United States
  • University of Miami Miller School of Medicine Schiff Center for Liver Disease
    Miami, Florida 33136, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • Triple O Research Institute, P.A
    West Palm Beach, Florida 33407, United States
  • Mercer University, Department of Internal Medicine
    Macon, Georgia 31201, United States
  • Indiana CTSI Clinical Research Center
    Indianapolis, Indiana 46202, United States
  • National Institutes of Health/Clinical Center
    Bethesda, Maryland 20892, United States
  • Be Well Medical Center
    Berkley, Michigan 48072, United States
  • AXCES Research Group
    Santa Fe, New Mexico 87505, United States
  • Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center
    New York, New York 10029, United States
  • NC TraCS Institute-CTRC; University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care
    Greenville, North Carolina 27834, United States
  • Rosedale Health & Wellness
    Huntersville, North Carolina 28078, United States
  • Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • St. Jude Children's Research Hospital
    Memphis, Tennessee 38105, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • The Crofoot Research, INC.
    Houston, Texas 77098, United States
  • Peter Shalit, M.D.
    Seattle, Washington 98104, United States
09

References and documents

Publications

  • Eron JJ, Cook PP, Mehrotra ML, Huang H, Caskey M, Crofoot GE, DeJesus E, Gorgos L, VanderVeen LA, Osiyemi OO, Brinson C, Collins SE. Lenacapavir Plus bNAbs for People with HIV and Susceptibility to Either Teropavimab or Zinlirvimab [Oral]. Conference on Retroviruses and Opportunistic Infections (CROI); 2024 3-6 March, Denver, CO.
  • Eron JJ, Little SJ, Crofoot G, Cook P, Ruane PJ, Jayaweera D, VanderVeen LA, DeJesus E, Zheng Y, Mills A, Huang H, Waldman SE, Ramgopal M, Gorgos L, Collins SE, Baeten JM, Caskey M. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study. Lancet HIV. 2024 Mar;11(3):e146-e155. doi: 10.1016/S2352-3018(23)00293-X. Epub 2024 Jan 30. PubMed 38307098 ↗
  • Eron J, Little SJ, Crofoot G, Cook P, Ruane PJ, Jayaweera D, DeJesus E, Walkman SE, Mehrotra ML, VanderVeen L, Huang H, Collins S, Baeten J, Caskey M. Lenacapavir with bNAbs Teropavimab (GS-5423) and Zinlirvimab (GS-2872) Dosed Every 6 Months in People with HIV [Oral 193]. Conference on Retroviruses and Opportunistic Infections (CROI); 2023 19-22 February, Seattle, WA
  • Selzer L, VanderVeen LA, Parvangada A, Martin R, Collins SE, Mehrotra M, Callebaut C. Susceptibility Screening to bNAbs Teropavimab (GS-5423) and Zinlirvimab (GS-2872) in ART-Suppressed Participants [Poster]. Conference on Retroviruses and Opportunistic Infections (CROI); 2023 19-22 February; Seattle, WA
  • Lisa Selzer, Sally Demirdjian, Ross Martin, Brie Falkard, Sean E. Collins, Joseph Eron, Laurie A. VanderVeen, Christian Callebaut. Resistance analyses during treatment of lenacapavir with broadly neutralizing antibodies in people with HIV (Poster WEPEB146) AIDS 2024; Munich, Germany
  • Selzer L, VanderVeen LA, Parvangada A, Martin R, Collins SE, Mehrotra M, Callebaut C. Susceptibility Screening of HIV-1 Viruses to Broadly Neutralizing Antibodies, Teropavimab and Zinlirvimab, in People With HIV-1 Suppressed by Antiretroviral Therapy. J Acquir Immune Defic Syndr. 2025 Jan 1;98(1):64-71. doi: 10.1097/QAI.0000000000003528. PubMed 39298557 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Jun 2022, 14 months.

Results were first posted in Jan 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Mar 23, 2021
StartActual
Apr 8, 2021
Primary completionActual
Jun 9, 2022
CompletionActual
Oct 26, 2023
Results first posted
Jan 27, 2025
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04811040
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Mar 23, 2021
Start date
Apr 8, 2021
Primary completion
Jun 9, 2022
Completion
Oct 26, 2023
Results posted
Jan 27, 2025
Last update
Jan 27, 2025

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenacapavir · Teropavimab · Zinlirvimab

Start the discussion